← Leaderboards
Suranganie F Dharmawardhane
University Of Texas Austin
$25,704,182
Attributed
$25,704,182
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,704,182 · 8
By mechanism
P20$23,065,254 · 2
SC3$1,609,042 · 1
S10$243,119 · 1
R16$230,950 · 1
R21$225,000 · 1
G12$187,379 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsInnovationAwardBreast Cancer CellMalignant Breast NeoplasmIn VivoMouse ModelTumor GrowthNeoplasm MetastasisBaseCancer CellTechnologyTrainingAffectProgramsLeadPrimary NeoplasmTumorResponseDoctor Of PhilosophyProductivityPuerto RicoPeer ReviewFunding
Grant awards (34)
Developmental Research Projects Program (DRPP)$2,384,459
P20 · FY2025 · GM · contact PI
MBQ-167 derivatives as antimetastatic cancer agents.$52,150
R16 · FY2025 · GM · contact PI
Developmental Research Projects Program (DRPP)$2,348,087
P20 · FY2024 · GM · contact PI
Flow cytometer for analysis of immune and other cell types$243,119
S10 · FY2024 · GM · contact PI
MBQ-167 derivatives as antimetastatic cancer agents.$89,400
R16 · FY2024 · GM · contact PI
Developmental Research Projects Program (DRPP)$1,293,675
P20 · FY2023 · GM · contact PI
MBQ-167 derivatives as antimetastatic cancer agents.$89,400
R16 · FY2023 · GM · contact PI
Developmental Research Projects Program (DRPP)$2,384,459
P20 · FY2022 · GM · contact PI
Developmental Research Projects Program (DRPP)$2,471,959
P20 · FY2021 · GM · contact PI
Targeting breast cancer progression$116,190
SC3 · FY2021 · GM · contact PI
Targeting breast cancer progression$112,500
SC3 · FY2021 · GM · contact PI
Developmental Research Project Program$2,484,418
P20 · FY2020 · GM · contact PI
Targeting breast cancer progression$112,500
SC3 · FY2020 · GM · contact PI
Developmental Research Project Program$2,497,800
P20 · FY2019 · GM · contact PI
Targeting breast cancer progression$112,500
SC3 · FY2019 · GM · contact PI
Targeting breast cancer progression$62,965
SC3 · FY2019 · GM · contact PI
Targeting breast cancer progression$112,500
SC3 · FY2018 · GM · contact PI
Developmental Research Project Program$2,033,297
P20 · FY2017 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$112,500
SC3 · FY2017 · GM · contact PI
Developmental Research Project Program$2,497,800
P20 · FY2016 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$112,500
SC3 · FY2016 · GM · contact PI
Developmental Research Project Program$2,669,300
P20 · FY2015 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$112,500
SC3 · FY2015 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$112,500
SC3 · FY2014 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$111,375
SC3 · FY2011 · GM · contact PI
CANCER RESEARCH CENTER$187,379
G12 · FY2010 · RR · contact PI
Molecular targets of soy isoflavones in breast cancer progression$112,500
SC3 · FY2010 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$93,312
SC3 · FY2010 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$112,500
SC3 · FY2009 · GM · contact PI
Molecular targets of soy isoflavones in breast cancer progression$100,200
SC3 · FY2008 · GM · contact PI
Resveratrol in breast cancer cell survival or apoptosis$72,306
R03 · FY2006 · CA · contact PI
Resveratrol in breast cancer cell survival or apoptosis$71,132
R03 · FY2005 · CA
REGULATORY ROLE OF RAC AND CDC42 ON TUMOR METASTASIS$112,500
R21 · FY2001 · CA
REGULATORY ROLE OF RAC AND CDC42 ON TUMOR METASTASIS$112,500
R21 · FY2000 · CA